SCHEMBL5636133

SCHEMBL5636133

N#CN/C(=N/c1ccc(F)cc1)Oc1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.74
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
CRHBP P24387 2/20 0.37
CRHR2 Q13324 2/20 0.37
TMPRSS15 P98073 2/20 0.36
PRSS1 P07477 1/20 0.36
ACR P10323 1/20 0.36
SLC22A2 O15244 1/20 0.36
SLC22A1 O15245 1/20 0.36
SLC22A3 O75751 1/20 0.36
PLAU P00749 1/20 0.36
ALDH1A1 P00352 2/20 0.36
NOS3 P29474 2/20 0.35
NOS1 P29475 2/20 0.35
KIF11 P52732 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5636135 1.00 KMT2A (0.74) KMT2AMEN1CYP1A2CYP2D6MAPT
SCHEMBL3402743 0.89 KMT2A (0.80) KMT2ACYP2D6MAPTCRHBPCRHR2
SCHEMBL2087129 0.89 KMT2A (0.80) KMT2ACYP2D6MAPTCRHBPCRHR2
SCHEMBL2087128 0.89 KMT2A (0.80) KMT2ACYP2D6MAPTCRHBPCRHR2
SCHEMBL4037230 0.84 KMT2A (0.72) KMT2AMEN1MAPTPRSS1ACR
SCHEMBL9273042 0.82 KMT2A (0.70) KMT2ACYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL9273040 0.82 KMT2A (0.70) KMT2ACYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL25643403 0.82 KMT2A (0.61) KMT2ACRHBPCRHR2ALDH1A1LMNA
SCHEMBL25643402 0.79 KMT2A (0.57) KMT2ACRHBPCRHR2ALDH1A1LMNA
SCHEMBL3391057 0.79 KMT2A (0.64) KMT2AMEN1MAPTPRSS1ACR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220856-B2 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2007-05-22 US disclosed
EP-1534681-A1 SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2005-06-01 EP disclosed
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2004-04-15 US disclosed
WO-2004002960-A1 SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists CCR5, CXCR3, CCR2 KMT2A 3541/4885MEN1 4119/4885CYP1A2 876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.